Elanco Lifts 2026 Outlook As Zenrelia And Credelio Quattro Drive 11% Sales Growth

The animal-health company raised its full-year revenue, EBITDA and EPS targets and hit its 2.9x net leverage goal sooner than it expected.

Share
Elanco Lifts 2026 Outlook As Zenrelia And Credelio Quattro Drive 11% Sales Growth

Elanco Animal Health, which makes medicines and vaccines for pets and farm animals, raised its 2026 outlook on Friday after third-quarter revenue rose 11% to $1.265 billion, or 9% on an organic constant-currency basis. It also reached its 2.9x net leverage target earlier than anticipated, the company said in an 8-K.

Price and mix lift the margin

Pet Health sales rose 14% to $608 million, and Farm Animal revenue rose 6% to $631 million. Within farm animals, cattle rose 17% to $339 million and swine rose 5% to $91 million, while poultry fell 7% to $201 million.

Price rose 4% overall, which CEO Jeff Simmons said exceeded the company's expectations, and volume rose 5%. Adjusted gross margin widened 300 basis points (3 percentage points) to 56.1%, which the company attributed mainly to higher pricing and favorable mix in U.S. Pet Health and global ruminants.

Adjusted EBITDA rose 23% to $243 million, and adjusted EPS climbed to $0.27 from $0.19. Reported net income was $18 million, against a $34 million loss a year earlier. Operating cash flow was $216 million, compared with $219 million.

New pet drugs carry the growth

Simmons said both Zenrelia and Credelio Quattro reached new market share highs in September, with competitive activity having "no fundamental impact" on their trajectory. Zenrelia had its largest revenue quarter ever, adding 1,600 clinics in the quarter to about 19,000 in the U.S.

Credelio Quattro also added 1,600 clinics, bringing penetration to over 16,500, or about 55%. It became Elanco's largest U.S. Pet Health branded product, passing Seresto. The company expects to launch it in the EU in the first quarter of 2027 after a positive opinion from the European Medicines Agency. Befrena moves into full launch in the first quarter of 2027.

Seresto brought in $49 million and Advantage $115 million; Seresto was hurt by a U.S. retailer inventory drawdown, the company said.

Higher targets and a debt milestone

Elanco now expects 2026 revenue of $5.155 billion to $5.18 billion, up from $5.09 billion to $5.14 billion in August. Adjusted EBITDA guidance rose to $1.05 billion to $1.065 billion from $1.01 billion to $1.035 billion, and adjusted EPS to $1.17 to $1.20 from $1.10 to $1.16. The innovation revenue target rose to $1.275 billion.

Net debt was $3.005 billion at quarter-end, 2.9x trailing adjusted EBITDA, down 0.7x from December 31, 2025. CFO Bob VanHimbergen said reaching the level early "unlocks accelerated capital allocation flexibility."

Fourth-quarter guidance calls for revenue of $1.19 billion to $1.215 billion, adjusted EBITDA of $185 million to $200 million and adjusted EPS of $0.16 to $0.19. The company reiterated its 2027 expectation of mid-single digit organic constant-currency revenue growth.

Elanco hosted its call at 8:00 a.m. Eastern Friday to walk through the fourth-quarter guidance and an early 2027 outlook.

Sources